GILD broke wedge to the upside. $80 likely next stopGILD broke wedge to the upside. $80 likely next stopLongby RyanDreBach1
Time to get defensive in $GILDThe global slowdown is coming and it is time to get defensive. Here we are reaching the end of the road to the downside in Gilead and a perfect instrument to work the flows with. We are tracking a break of the channel to unlock the +11% move. Let's see how it plays out over the coming days. Best of luckLongby ridethepigUpdated 9
GILD ready to break outBounce off resistance. Had strong volume to get there. Above all the EMA's. Waiting for this to pullback a little farther to jump in. Stop below the previous weeks' candle. Longby BruceD9753
GILD - Nov 15I totally missed this rally after the breakout from 64. Previous resistance is at 69. It would be interesting to see how GILD performs around that level. Watching for a jump of the cliff move from the ladder it is climbing. Targeting long 65 Put Nov 15.by imzeeshan5
GILD TECHNICAL ANALYSIS CHART PATTERNFRIENDS AFTER LONG DOWN TREND NOW WE HAVE SEEN A TRIPLE BOTTOM PATTERN IN MY OPINION AFTER BREAKING THE NECKLINE IT WILL GO FOR LONG TIL THE NEXT RESISTANCE AREA OR MORE. NOTE: WE CANT ENTER THE TRADE UNTIL IT BREAK THE NECKLINE OF THE PATTERN.Longby AdeelMahmood334
$GILD BREAKOUT ON THE WAY IN GILEAD SCIENCES INCGilead traded well today on the news it will be investing $5.1 billion in EURONEXT:GLPG which will raise its stake from 12% to 22% with the a future target of 29.9% ownership on approval by the shareholders of Galapagos. The market seems happy with the move, even as biotech stocks have been under pressure lately. Decisions out of the White House haven't been helping, as the government continues to keep a close eye on drug prices. Also on Monday Wells Fargo analysts upgraded Gilead Sciences to an outperform rating and slapped an $88 price target on the name. That implies 33% upside from Friday's closing price and would send Gilead stock more than 10% above its 52-week high. AVERAGE ANALYSTS PRICE TARGET $88 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT P/E RATIO 15 SHORT INTEREST 1% Company Description Gilead Sciences , Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. Longby RedHotStocks2214
GILD nearing pullback at top of long-term channelGILD nearing pullback at the top of it's multiyear channel.Shortby RyanDreBach3
GILD Showing some positive price actionTesting the top of a long term range. May fall back but if it breaks and pushes through 200 could see a significant move up.Longby WadeYendall7
Needs to get $104.55chart doesn't look good until we move through/ hold above ICHI cloudby noam_chom1
GILD Double White Candles Test ResistanceGilead Sciences, Inc. is testing the resistance to begin completion of this longer-term bottoming formation. The W bottom formation has tiers of resistance to overcome. Hybrid Leading Indicators show strengthening pattern. by MarthaStokesCMT-TechniTrader1
$GILD Time to be BULLISH on Gilead Sciences.Gilead reported earnings on Thursday and it may be finally turning the corner. GILD was considered a one trick pony due to the success of its Hepatitis drugs, which unfortunately have starting to drop in revenue. That decline has been meet with a rising revenue stream from new HIV treatments, which tend to be longer term treatments than Hepatitis cases. As a result of recent acquisitions, Oncology is also a growing revenue stream with Yescarta more than doubling revenue to $96m in the first quarter. GILEAD also has a sizable cash at hand of $30 Billion along with a very strong balance sheet. Analysts have a overweight rating on the stock and a average price target of $81, we expect some upgrades in the days to come. NASDAQ:GILD Company Description Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.Longby RedHotStocks8
Gilead Sciences - earnings after the bellGilead Sciences, Inc. is expected to report earnings after market close. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.53. The reported EPS for the same quarter last year was $1.37. Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for. by PJVN1
$gild Gild versus its 100d, failed to break three times, looks to be forming a base. GLTALongby dmjs123